


RECEIVED
CENTRAL FAX CENTER

SEP 07 2006

AMENDMENT TO THE CLAIMS

The Listing of Claims presented below will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A compound having the structure:



(I)

or pharmaceutically acceptable salt, ester, or salt of such ester;

wherein ~~R₁-R₄~~ R₁, R₂ and R₄ are each independently hydrogen or an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety;

R₃ is an aryl moiety having one of the following structures:




R₅ and R₆ are each independently hydrogen or an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, and wherein ~~R₅ and R₆~~ R₅ and R₆, taken together, may form a cyclic aliphatic, heteroaliphatic, aliphatic(aryl), heteroaliphatic(aryl), aliphatic(heteroaryl) or heteroaliphatic(heteroaryl) moiety, or an aryl or heteroaryl moiety;

wherein each of the foregoing aliphatic and heteroaliphatic moieties may be substituted or unsubstituted, cyclic or acyclic, saturated or unsaturated or linear or branched; and each of the foregoing aryl, heteroaryl, alkylaryl or alkylheteroaryl moieties may be substituted or unsubstituted; ~~and~~

~~pharmaceutically acceptable derivatives thereof.~~

2. (Currently Amended) The compound of claim 1, wherein the compound has the structure (II):



or pharmaceutically acceptable salt, ester, or salt of such ester;

wherein R_1 , R_2 and R_4 are each independently hydrogen or an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety;

R_3 is an aryl moiety having one of the following structures:



R_5 and R_6 are each independently hydrogen or an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, and wherein R_5 and R_6 , taken together, may form a cyclic aliphatic, heteroaliphatic, aliphatic(aryl), heteroaliphatic(aryl), aliphatic(heteroaryl) or heteroaliphatic(heteroaryl) moiety, or an aryl or heteroaryl moiety;

wherein each of the foregoing aliphatic and heteroaliphatic moieties may be substituted or unsubstituted, cyclic or acyclic, saturated or unsaturated or linear or branched; and each of the foregoing aryl, heteroaryl, alkylaryl or alkylheteroaryl moieties may be substituted or unsubstituted; and


~~pharmaceutically acceptable derivatives thereof.~~

3. (Original) The compound of claim 1, wherein R^1 is hydrogen or an alkyl, heteroalkyl, aryl or heteroaryl moiety substituted with Z, wherein Z is hydrogen, $-(CH_2)_qOR^Z$, $-(CH_2)_qSR^Z$, $-(CH_2)_qN(R^Z)_2$, $-(C=O)R^Z$, $-(C=O)N(R^Z)_2$, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -

(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, wherein q is 0-4, and wherein each occurrence of R^Z is independently hydrogen, a protecting group, a solid support unit, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety; wherein each of the foregoing alkyl or heteroalkyl moieties may be substituted or unsubstituted, linear or branched, cyclic or acyclic, saturated or unsaturated; and wherein each of the foregoing aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moieties may be substituted or unsubstituted.

4. (Original) The compound of claim 3, wherein R^1 is hydrogen, lower alkyl, a substituted or unsubstituted phenyl or -(lower alkyl)phenyl moiety, $-(CH_2)_nOR^Z$, $-[(CH_2)_nO]_mR^Z$, $-(CH_2)_n-Ar-(CH_2)_mOR^Z$; wherein n and m are each independently integers from 1-6, Ar represents a substituted or unsubstituted aryl or heteroaryl moiety, and R^Z is independently hydrogen, a protecting group, a solid support unit, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety; wherein each of the foregoing alkyl or heteroalkyl moieties may be substituted or unsubstituted, linear or branched, cyclic or acyclic, saturated or unsaturated; and wherein each of the foregoing aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moieties may be substituted or unsubstituted.

5. (Original) The compound of claim 4, wherein R^1 is hydrogen, ethyl, or has one of the structures:



wherein R^Z is as defined in claim 4.

6. **(Original)** The compound of claim 1, wherein R^2 is hydrogen or an alkyl, heteroalkyl, aryl or heteroaryl moiety substituted with Z, wherein Z is hydrogen, $-(CH_2)_qOR^Z$, $-(CH_2)_qSR^Z$, $-(CH_2)_qN(R^Z)_2$, $-(C=O)R^Z$, $-(C=O)N(R^Z)_2$, or an aliphatic, heteroaliphatic, aryl, heteroaryl, $-(aliphatic)aryl$, $-(aliphatic)heteroaryl$, $-(heteroaliphatic)aryl$, or $-(heteroaliphatic)heteroaryl$ moiety, wherein q is 0-4, and wherein each occurrence of R^Z is independently hydrogen, a protecting group, a solid support unit, or an aliphatic, heteroaliphatic, aryl, heteroaryl, $-(aliphatic)aryl$, $-(aliphatic)heteroaryl$, $-(heteroaliphatic)aryl$, or $-(heteroaliphatic)heteroaryl$ moiety; wherein each of the foregoing alkyl or heteroalkyl moieties may be substituted or unsubstituted, linear or branched, cyclic or acyclic, saturated or unsaturated; and wherein each of the foregoing aryl, heteroaryl, $-(alkyl)aryl$, $-(alkyl)heteroaryl$, $-(heteroalkyl)aryl$, or $-(heteroalkyl)heteroaryl$ moieties may be substituted or unsubstituted.

7. **(Original)** The compound of claim 6, wherein R^2 is hydrogen, lower alkyl, a substituted or unsubstituted phenyl or $-(lower\ alkyl)phenyl$ moiety, $-(CH_2)_nOR^Z$, $-[(CH_2)_nO]_mR^Z$, $-(CH_2)_n-Ar-(CH_2)_mOR^Z$; wherein n and m are each independently integers from 1-6, Ar represents a substituted or unsubstituted aryl or heteroaryl moiety, and R^Z is independently hydrogen, a protecting group, a solid support unit, or an aliphatic, heteroaliphatic, aryl, heteroaryl, $-(aliphatic)aryl$, $-(aliphatic)heteroaryl$, $-(heteroaliphatic)aryl$, or $-(heteroaliphatic)heteroaryl$ moiety; wherein each of the foregoing alkyl or heteroalkyl moieties may be substituted or unsubstituted, linear or branched, cyclic or acyclic, saturated or unsaturated; and wherein each of the foregoing aryl, heteroaryl, $-(alkyl)aryl$, $-(alkyl)heteroaryl$, $-(heteroalkyl)aryl$, or $-(heteroalkyl)heteroaryl$ moieties may be substituted or unsubstituted.

8. **(Original)** The compound of claim 6, wherein R^2 is hydrogen or has one of the structures:



wherein R^Z is as defined in claim 6.

9. **(Cancelled)**


10. (Cancelled)

11. (Original) The compound of claim 1, wherein R^4 is hydrogen or an alkyl, heteroalkyl, aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moiety; wherein each of the foregoing alkyl or heteroalkyl moieties may be substituted or unsubstituted, linear or branched, cyclic or acyclic, saturated or unsaturated; and wherein each of the foregoing aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moieties may be substituted or unsubstituted.


12. (Original) The compound of claim 11, wherein R^4 is hydrogen alkyl or heteroalkyl.

13. (Original) The compound of claim 1, wherein R^5 and R^6 are each independently hydrogen or an alkyl, heteroalkyl, aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moiety; or wherein R^5 and R^6 , taken together, form a substituted or unsubstituted, saturated or unsaturated cyclic moiety comprising 5-12 carbon atoms, 0-5 oxygen atoms, 0-5 sulfur atoms and 1-5 nitrogen atoms; and wherein each of the foregoing alkyl or heteroalkyl moieties may be substituted or unsubstituted, linear or branched, cyclic or acyclic, saturated or unsaturated; and wherein each of the foregoing aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moieties may be substituted or unsubstituted.


14. (Original) The compound of claim 1, wherein $-NR^5R^6$ is one of the following the structures:



16. (Original) The compound of claim 1 having the structure:




17. (Previously Amended) A compound having the structure:



Claims 18-21: Cancelled

22. (Previously Amended) A compound having the structure:



23. (Currently Amended) ~~A collection of compounds comprising two or more of the compounds of claim 1 or 2~~ A library of compounds comprising a plurality of library members, wherein at least two library members are a compound of claim 1 or 2.

Claims 24-25: Cancelled

26. **(Currently Amended)** The ~~collection~~ library of claim 23, wherein the ~~collection~~ library comprises at least 100 compounds.
27. **(Currently Amended)** The ~~collection~~ library of claim 23, wherein the ~~collection~~ library comprises at least 1,000 compounds.
28. **(Currently Amended)** The ~~collection~~ library of claim 23, wherein the ~~collection~~ library comprises at least 2,000 compounds.
29. **(Currently Amended)** The ~~collection~~ library of claim 23, wherein the ~~collection~~ library comprises at least 10, 000 compounds.
30. **(Currently Amended)** A pharmaceutical composition comprising:
a compound of any one of claims 1, 2, 5, 8, ~~10, 14, and 15-22~~ 14, 15-17 and 22; and
a pharmaceutically acceptable carrier.

Claims 31-39. **Cancelled**